COVID 19 Vaccination Clinic
Fiveways Surgery is proud to deliver COVID 19 vaccination to our patients aged 12 years and over.
Fiveways Surgery is committed to your safety during a COVID-19 outbreak and has implemented the following:
- We screen all patients to make sure they have no symptoms and have not been to an exposure site.
- We see all symptomatic patients via telehealth and when necessary in person, outside of the clinic wearing appropriate PPE. Our new centre will have a dedicated room for viral assessment and treatment.
- We request all patients to wear a mask at all times and require our staff providing clinical care to do the same for your and their own safety.
- We have deployed HEPA filters throughout the clinic to reduce the risk of airborne transmission.
- All surfaces are regularly cleaned with Viraclens which has been proven to disinfect SarsCoV2/COVID19.
- All our staff are vaccinated and take precautions to avoid exposure to COVID in their personal lives. We commenced providing vaccination to the community at the commencement of the COVID-19 vaccination program and continue to do so.
- If you need a referral for a COVID-19 test, please book a telehealth appointment so we can assess if you require one. Testing locations can be found here for Qld Health sites; here for Respiratory clinics, or via Sullivan and Nicolaides, QML or 4Cyte Patients must wear an appropriately fitted mask at all time. Failure to comply may result in the termination of the doctor-patient relationship.
WE ARE NOW ABLE TO OFFER BOTH ASTRA ZENECA AND PFIZER COMMINRATY COVID-19 VACCINATIONS. TO BOOK IN FOR A COVID-19 VACCINATION, PLEASE CLICK ON THE BOOK NOW BUTTON.
The COVID-19 Vaccination Clinics are run as a nurse facilitated clinic and do not allow time for consultations or questions with your GP. If you have any questions or concerns about receiving the vaccination, you are required to book an appointment with your usual GP first.
Important information about the PFIZER COVID-19 Vaccination
A very large clinical trial showed that Pfizer is effective in preventing COVID-19 in people aged 12 years and older. People who had two doses of Pfizer were about 95 percent less likely to get symptomatic COVID-19 than people who did not get the vaccine. It was equally effective in people over the age of 65 years, as well as people with some stable pre-existing medical conditions.
Protection against COVID-19 starts from about 2–3 weeks after the first dose. While one dose may give some protection, it may only last for the short term. Two doses will give optimal protection. No vaccine is 100 percent effective, so it is possible that you can still get sick from COVID-19 after vaccination.
Special circumstances to discuss before vaccination
People with precautionary conditions for Pfizer
People with a history of any of the following conditions can receive Pfizer but advice should be sought from a GP, immunisation specialist or cardiologist about the best timing of vaccination and whether any additional precautions are recommended:
- Recent (i.e., within the past 6 months) inflammatory cardiac illness. For example myocarditis, pericarditis, endocarditis
- Acute rheumatic fever (i.e., with active myocardial inflammation) or acute rheumatic heart disease
- Acute decompensated heart failure.
People with weakened immune systems (immunocompromise)
People with immunocompromise includes those who have a medical condition that weakens their immune system. It also includes those who may be taking medications that suppress their immune system.
The Australian Government strongly recommends people with immunocompromise receive COVID-19 vaccination. Pfizer is not a live vaccine. It is safe in people with immunocompromise.
People with immunocompromise, including those living with HIV, have a higher risk of severe illness from COVID-19, including a higher risk of death.
Clinical trials for Pfizer did not include people with immunocompromise, except for a small group of people with stable HIV. We do not know if Pfizer is as effective in people with immunocompromise compared to the rest of the population. It is possible that Pfizer might not be as effective in people with immunocompromise as it is in the general population. It is important to continue other preventative measures such as physical distancing after vaccination.
Women who are pregnant or breastfeeding
Women and adolescents who are pregnant should be routinely offered Pfizer or Moderna at any stage of pregnancy. If you are trying to become pregnant you do not need to delay vaccination or avoid becoming pregnant after vaccination.
Pregnant women with COVID-19 have an increased risk of severe illness and adverse pregnancy outcomes. Real-world evidence has shown that Pfizer is safe for pregnant women and breastfeeding women.
If you are breastfeeding, you can have Pfizer. You do not need to stop breastfeeding after vaccination.
People with a history of COVID-19
If you have had COVID-19 in the past, tell your immunisation provider. COVID-19 vaccination can be deferred for up to six months after the acute illness in those who have had confirmed SARSCoV-2 infection, as evidence suggests that past infection reduces the risk of reinfection for at least 6 months. However, vaccination can start when they have recovered from the symptomatic infection. It is reasonable to be vaccinated earlier than 6 months following infection for some people. Discuss with your doctor or immunisation provider. If you have ongoing illness from COVID-19, discuss the best timing of vaccination with your treating doctor.
Pfizer and children
Pfizer has been provisionally approved for use in people aged 12 years or older, and cannot be given to younger people
SARS-CoV-2 could potentially still infect a vaccinated person. Even if they have no symptoms or only mild symptoms, they could still pass it on to others. However, the COVID-19 vaccines currently used in Australia is effective in reducing the likelihood of a vaccinated person transmitting the virus to close contacts if the person is infected
UPDATED INFORMATION from ATAGI re: AstraZeneca Vaccine – 17 June 2021
The Australian Technical Advisory Group on Immunisation (ATAGI) have reviewed their advice on the AstraZeneca vaccine. They have recommended that Pfizer is the preferred vaccine for people aged under 60 years.
This doesn’t change who is currently eligible for a COVID-19 vaccine, but it means if you are under 60 it is preferred you get the Pfizer vaccine.
Why has the advice changed?
ATAGI have made this recommendation because of new evidence that shows the risk of thrombosis with thrombocytopenia syndrome, or TTS (which is a rare blood clotting syndrome) in the 50 – 59 age
group is higher than initially thought.
I’ve had my first dose of AstraZeneca, should I get Pfizer for my second dose?
No, this isn’t necessary. If you have had your first AstraZeneca vaccine dose without any serious side effects, you can receive your second dose as planned. To ensure maximum long term immunity, it is important you receive two doses of the same COVID-19
UPDATED INFORMATION – 21 May 2021 (health.gov.au/covid19-vaccines)
There has been a link between the AstraZeneca COVID-19 vaccine and a rare condition called thrombosis with thrombocytopenia syndrome (TTS). This condition appears to be more common in younger adults.
Comirnaty (Pfizer) is the preferred COVID-19 vaccine for adults under 60 years of age at this time.
All adults are recommended to be vaccinated against COVID-19. The risk of severe illness and death from COVID-19 progressively increases with age in older adults. This means that older adults will have a higher benefit from vaccination.
More information on what this means can be found at www.health.gov.au/covid19-vaccines
What is thrombosis with thrombocytopenia syndrome (TTS)?
This is a rare side effect of the AstraZeneca COVID-19 vaccine. It can be very serious and can cause long-term disability and death. Comirnaty (Pfizer) is not associated with a risk of TTS.
The condition causes thrombosis (blood clotting) and thrombocytopenia (low blood platelet counts). It is different from general clotting disorders such as deep vein thrombosis (DVT) or pulmonary embolism (PE). TTS can occur at different parts of the body, including the brain (called cerebral venous sinus thrombosis) and in the abdomen (idiopathic splanchnic vein thrombosis). The low level of blood platelets can potentially cause bleeding.
- Thrombosis is the formation of a blood clot, which prevents blood flowing normally through the body. While thrombosis is usually a normal response to prevent bleeding (e.g. following injury), in this case this process is abnormal.
- Thrombocytopenia is a condition in which you have a low blood platelet count. Platelets (thrombocytes) are blood cells that help blood clot. Platelets stop bleeding by clumping and forming plugs in injured blood vessels.
When does TTS typically occur?
TTS typically occurs around 4 to 28 days after vaccination with AstraZeneca COVID-19 vaccine.
How common is TTS?
TTS is rare. It is currently estimated to affect about 1-2 per 100,000 people who receive the AstraZeneca COVID-19 vaccine. But for those under 50 years of age, the rate is currently estimated to be higher. These estimates are based on the small numbers of people who have been vaccinated in Australia but are similar to rates seen in some countries overseas. They will be updated as further information become available.
Are any groups more at risk of TTS?
The rate of TTS reported in Australia and overseas is higher in younger adults and it may be more common in women. However cases have also been reported in men and in older people. It is not yet clear if women are at higher risk. More women than men have been vaccinated in some countries as they are a large proportion of frontline healthcare workers and have been prioritised for vaccination.
Based on current information, we do not know if there are any pre-existing medical conditions that may contribute to developing TTS or make it worse if it occurs.
What symptoms does TTS usually cause?
If you experience the following symptoms after vaccination you should seek medical attention immediately:
- A severe persistent headache with additional features:
- appears at least 4 days after vaccination
- does not improve with simple painkillers
- may be worse when lying down
- may be accompanied by nausea and vomiting
- Neurological symptoms such as:
- blurred vision
- difficulty with speech
- Shortness of breath
- Chest pain
- Swelling in your leg
- Persistent abdominal (belly) pain
- Tiny blood spots under the skin away from the site of injection.
Do the benefits of the AstraZeneca vaccine outweigh any risk?
Yes. The benefits of vaccination clearly outweigh the risks in many circumstances. This is particularly so for older people who have a higher risk of severe illness or death from COVID-19.
Cases of TTS have occurred in people of all ages. However, the risk of TTS appears to be lower in those over 50 years old than in younger adults.
For people under 60 years of age, Comirnaty (the Pfizer COVID-19 vaccine) is preferred. The risks of dying or having severe disease from COVID-19 are generally lower in healthy younger adults and they have a higher (although still rare) risk of TTS after vaccination compared with older adults.
What if you are aged 50 and under and are booked in to receive your first dose of AstraZeneca?
If you are under the age of 60, Comirnaty (the Pfizer vaccine) is preferred for you. If you are booked in to receive your first dose of the AstraZeneca COVID-19 vaccine and you are younger than 60 years old, please talk to your health professional. Fiveways will continue with the second dose for this age group where the first has already been administered at Fiveways Suegery
How do people aged under 50 years book an appointment for the Pfizer vaccine? Where is it available?
The COVID-19 vaccination program has been modified in light of the ATAGI advice. More Pfizer vaccination sites will become available around the country in line with increasing supplies. You can check your eligibility and where to get a vaccine using the eligibility checker.
What if you have received your first dose of AstraZeneca and are due for your second dose?
People who have received their first dose without any serious adverse events can be confident in getting their second dose of the of AstraZeneca COVID-19 vaccine. UK data suggests that the risk of TTS is much lower after the second dose, with 15 cases reported to date out of 9.0 million second doses of the AstraZeneca COVID-19 vaccine given. This translates into an estimated rate of 1.7 cases per million doses.
What about people with heparin induced thrombocytopenia (HIT), central venous sinus thrombosis (CVST), idiopathic splanchnic vein thrombosis or antiphospholipid syndrome with thrombosis?
TTS is different to these certain rare conditions, although there are similarities between TTS and each of these conditions. As a precaution, in people with a history of heparin-induced thrombocytopenia, central venous sinus thrombosis, idiopathic splanchnic vein thrombosis or antiphospholipid syndrome with thrombosis, the Pfizer (Comirnaty) vaccine is recommended over the AstraZeneca COVID-19 vaccination at this time. The Pfizer (Comirnaty) vaccine is not associated with TTS.
Is the AstraZeneca vaccine safe in people who have had blood clots in the past?
If you have had other types of blood clots in the past, or if you have risk factors for blood clots, you can still have the AstraZeneca vaccine. There is no evidence that people who have had a past history of other types of blood clots have an increased risk of developing TTS or becoming more ill from it if it occurs.
People with the following conditions can receive the AstraZeneca COVID-19 Vaccine:
- History of blood clots in typical sites
- Increased clotting tendency that is not immune-mediated
- Family history of blood clots
- History of ischaemic heart disease or stroke
- Current or past thrombocytopenia (low platelet count)
- Those receiving anticoagulation therapy
The overall rate of blood clots has not risen in countries that have extensively used the AstraZeneca vaccine with millions of doses administered. Blood clots occur commonly in the population, and not all blood clots that occur after AstraZeneca COVID-19 will be caused by the vaccine. If you develop a blood clot after vaccination, your doctor can do blood tests to determine the cause.
More information about the vaccine can be found using the links below:
AstraZeneca vaccine and the COVID-19 vaccination program – Patient information – here
Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca – here
COVID-19 vaccination – Preparing for COVID-19 vaccination – here
COVID-19 vaccination – After your AstraZeneca vaccine – here
You can report side effects to the TGA by using their online form.
In order to safely vaccinate as many patients as possible in a short period of time we need you to follow the process outlined on this webpage.
All patients will be required to complete a questionnaire and consent form before attending for their vaccination. If you do not complete your form or arrive late for your vaccination you will be asked to reschedule.
In order to avoid disruptions to the usual care of our existing patients we strongly encourage you to use our online booking system and complete the electronic consent form. We ask family members to help the elderly to do this.
If you wish to discuss the merits of the vaccination and/or your concerns about risks/benefits please book a telehealth appointment.
There are no fees for the COVID 19 vaccination or discussions solely about the COVID 19 vaccination – these consultations will be bulk billed.
You may experience minor side effects following vaccination. Most side effects last no more than a couple of days and you will recover without any problems.
Common reactions to vaccination include:
- pain, redness and/or swelling where you received the needle
- mild fever
Serious reactions such as allergic reactions are extremely rare. They usually occur within 15 minutes of receiving a vaccine. After you receive your vaccine, you should wait this amount of time before you leave to ensure your safety in case a reaction occurs.
As with any vaccine or medicine, there may be rare and/or unknown side effects. A possible rare side effect of blood clots in the brain or other body sites is currently being investigated. It is not known if this condition is caused by the vaccine – this is currently being investigated. This condition has been reported in the 4-20 days after vaccination with COVID-19 AstraZeneca vaccine at a rate of about 1 to 8 people for every one million people vaccinated.
Patients will be required to book using the link here
Patients will be required to complete the consent form via the link above. If you cannot use online booking or you book by phone you can complete your consent form here.
Patients will need to attend the clinic at the time of their appointment – late arrivals will be required to re-book.
If you wish to ask questions about the vaccine – arrange an appointment prior to the vaccination date.
Please wear a short sleeved shirt with easy access to your upper arm. If you are unwell do not attend the clinic. If you wish you may wear a mask.
When you arrive at the clinic, turn right at reception and let our receptionist know your name. Take a seat in the marked waiting area.
Patients will be asked to sit in turn and move up one seat as patients move through the vaccination clinic. When it is your turn please follow the floor signs when the bell rings. The bell indicates the nurse is ready for the next patient.
When it is your turn, the nurse will ask you to state your name and date of birth and confirm your consent to receive the vaccination. Once you have been vaccinated you will receive a card with the date and batch number of the vaccine.
Please follow the signs to the receptionist to book your 2nd dose in 12 weeks time.
Please wait in the clinic for 15 minutes. If you feel unwell let our receptionist know. If you feel well and your time has elapsed you may leave the clinic.
Patient Information COVID19 Vaccination
The Federal Government has produced a number of educational materials available here
Watch our Covax video run through
Thank you for helping us to deliver a safe and effective vaccination drive for COVID 19. Your understanding and patience is appreciated.